ArticleFrontiers in medicine2025
The diagnostic value of endobronchial ultrasound-guided transbronchial needle aspiration for bronchial anthracosis/anthracofibrosis with mediastinal enlarged lymph node.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- EBUS-guided Cryobiopsy-Proven Anthracotic Mediastinal Lymph Node Mimicking Malignancy on FDG PET-CT: A Case Report.Saudi journal of medicine & medical sciencesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To explore the value of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) in patients of bronchial anthracosis (BAC)/bronchial anthracofibrosis (BAF) with enlarged mediastinal lymph nodes. Methods: A retrospective analysis was conducted on 5,589 bronchoscopies performed between January and December 2023. Among them, 62 patients were diagnosed with BAC, including 30 cases of BAF. Patients were categorized into BAF and non-BAF groups. Clinical data, laboratory findings, high-resolution computed tomography (HRCT) results, bronchoscopic features, and EBUS-TBNA outcomes were analyzed and compared between the two groups. Results: The overall incidence rates of BAC and BAF were 1.11 and 0.54%, respectively, with BAF accounting for 48.4% of all BAC cases. Compared to the non-BAF group, the BAF group exhibited higher frequencies of bronchial stenosis, mediastinal lymphadenopathy, and lymph node calcifications on HRCT. EBUS-TBNA cytology predominantly revealed lymphocytic infiltration and pigment-laden macrophages, with some findings of granulomatous inflammation and malignant cells. There was no significant difference in the overall diagnostic yield of EBUS-TBNA between the two groups. Conclusion: EBUS-TBNA is a highly valuable diagnostic tool for differentiating BAC/BAF with mediastinal lymphadenopathy. It provides crucial pathological insights, especially in cases potentially involving malignancy or granulomatous disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.